Real world VOYAGER data show Vabysmo works across major retinal conditions in everyday clinical practice

Roche has presented new data from the VOYAGER study at the EURETINA 2026 Annual Meeting in Vienna, Austria, looking at how well Vabysmo (faricimab) works, how long its effects last and how safe it is in neovascular age related macular degeneration (nAMD), diabetic macular oedema (DME) and macular oedema following retinal vein occlusion (RVO). Across every cohort, the real world results matched those from the Phase III trials. Eyes that had not been treated before gained vision and showed strong anatomical improvement, while eyes that had previously been treated kept stable or better vision and saw improved anatomy. No new safety signals emerged.

VOYAGER is the largest prospective, non interventional real world dataset on Vabysmo, with more than 5,000 patients enrolled across a wide range of clinical settings around the world. Advanced AI enabled analysis of retinal imaging also confirmed rapid and meaningful anatomical drying, which supports Vabysmo’s position as a standard of care in routine practice.

In the nAMD and DME cohorts, after 12 months of treatment, vision and central subfield thickness improved in previously untreated eyes, while previously treated eyes held their vision steady and still improved in thickness. Both forms of RVO also responded to treatment. In central or hemi RVO, vision and central subfield thickness got better in both untreated and previously treated eyes after six months. In branch RVO, untreated eyes improved on both measures after six months, while previously treated eyes kept stable vision and showed better thickness.

Across all cohorts, the proportion of eyes with subretinal fluid or intraretinal fluid fell consistently in both untreated and previously treated eyes. In the nAMD and DME groups, patients received fewer injections in months 7 to 12 than in months 1 to 6, which points to treatment intervals being stretched.

The detailed results were as follows:

Levi Garraway, MD, PhD, Roche’s chief medical officer and head of global product development, said the results show that the efficacy and safety seen in the pivotal Vabysmo studies carry over directly into routine care around the world. He said the lasting vision gains and meaningful drying seen in VOYAGER strengthen Vabysmo’s role in meeting important unmet needs for people with retinal conditions.

Professor Robyn Guymer, chair of the VOYAGER Steering Committee and deputy director of the Centre for Eye Research Australia, said doctors in daily practice treat varied patients with complicated treatment histories who often would not meet the strict entry criteria of controlled Phase III trials. She said the latest VOYAGER data give physicians worldwide confidence that Vabysmo delivers lasting vision gains, meaningful drying and an established safety profile in everyday practice, whether a patient is starting treatment for the first time or switching from another therapy.

Overall, Vabysmo’s safety profile in VOYAGER was generally consistent with that established in the Phase III studies in nAMD, DME and RVO.

---

---

Related Topics and Keywords

retinal, retinal conditions, Roche, VOYAGER